sanofi

The Office of the Vermont Attorney General
109 State St
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

30 March 2023

RE: Notification of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

On February 24, 2023, the Food & Drug Administration (FDA) approved ALTUVIIIO™ (efanesoctocog alfa) for the treatment of hemophilia A, a rare and life-threatening bleeding disorder. Bioverativ Therapeutics Inc., a Sanofi company, (referred to herein as "Sanofi"), manufactures ALTUVIIIO™, which has a wholesale acquisition cost (WAC) that exceeds the threshold set for a specialty drug under the Medicare Part D program. Therefore, pursuant to 18 V.S.A. § 4637(b), Sanofi hereby provides written notice to the Office of the Vermont Attorney General that it introduced ALTUVIIIO™ to the commercial market on March 27, 2023. We have provided information about the new prescription drug in the grid below.

Manufacturer	Bioverativ Therapeutics Inc.
Product Name	ALTUVIIIO™ (efanesoctocog alfa)
NDC	71104-0978-08
Date of Introduction to Market	*March 27, 2023*

In providing this notice, Sanofi expressly reserves any and all rights or claims it may have with respect to RSA § 318:68, the company's interpretation thereof, or the statute's application to Bioverativ Therapeutics Inc., Sanofi, or any other entity affiliated with or otherwise under the control of Sanofi.

Sincerely,

Phillip Ridolfi
Head of Business Operations and Support, Sales Support
55 Corporate Drive
Bridgewater, NJ 08807
Phillip.Ridolfi@sanofi.com